contact us
sort news by author
Andy Peel, Caitlin Wilkinson, Caoimhe McElduff, Charlotte Stockton, Charlotte Morgan, David Laws, Edward Jones, Emma Petela, GK Strategy, Harry Shackleton, Ian Perrin, Ioan Phillips, Isabelle Hillson, Jack Sansum, James Page, Jamie Cater, Jennifer Berger, Joe Berkhout, Joe Cormack, Johnny Munro, Louise Allen, Luke Kennedy, Mark Fuller, Martin Summers, Megan Baxter, Ned Lamb, Olivia Rohll, Rebecca Lury, Robin Grainger, Sarah De Rosa, Thomas Lambton, Tim Farazmand, Tim Swabey, Viya Nsumbu,
sort news by category
Insight, Strategy, Impact,
awards, B2G, Bills, Boris, Boris Johnson, Brexit, business, careers, climate change, commissioning, Communications, Consumer, consumer demands, Crisis comms, culture, Devolution, Digital, Due Diligence, Education, Energy, Energy and Environment, Environment, Equality, ESG, EU, europe, Financial Services, general election, General News, GK culture, gk report, Government, government affairs, Health, health funding, Healthcare, housing, HS2, infrastructure, insight, internship, Investment, Investor, Investor Backed Businesses, Investor Services, investors, Jeremy Corbyn, labour conference, Legislation, local government, mental health, mental health services, nationalisation, NHS, No deal, parliament, pharma, Planning, policy, Political Due Diligence, Politics, Pride Month, Prime Minister, Private Equity, Public Affairs, Public Relations, Queen's Speech, regulation, sales, Select Committee, Social Care, Strategic Communications, students, sustainability, Technology, The Conservative Party, The Labour Party, Transport, uk, UK Politics, university, Waste, women, Workplace,
Private Equity investment in Pharma – why is the UK bucking the global trend?
In recent years we’ve become used to claims that the impasse of Brexit is drying up investment in UK life sciences. The argument also goes that global investment by pharmaceuticals in R&D – predicted to grow to $181 billion by 2022 – will instead flow to other countries. There is evidence that can support this theory but if you scrape below the surface and look at investment by private equity into life sciences the picture looks quite different. The figures actually suggest that...
Artificial Intelligence: UK ‘pharmatech’ industry growth
Artificial Intelligence (AI) has been a mainstay in the public’s vocabulary for several years now. Tech revolutionaries have painted a futuristic and transformed world, if not a dystopian one; but only recently have we started to understand what this means for the ordinary citizen, such how it is transforming consumer healthcare. The ever-faster power of computer processors, the ability to house and...
